



COVID-19 treatment: High time for Antimicrobial Stewardship Program
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Summary
Last several months, the World is witnessing Coronavirus disease 2019 (COVID-19) pandemic caused by the new-
ly identified Coronavirus. Due to the fast and easy disease spread as well as its severity, currently this pandemic is 
dominating every aspect of the global healthcare systems but also it outstandingly influences every side of our lives 
including the global economy. Almost all COVID-19 treatment guidelines advocate the rational use of antibiotics, but 
if we analyse the reports published so far, it is evident that about 70% up to even 100% of patients are treated with 
antibiotics. This antibiotic misuse highlights the urgent need for launching the Antimicrobial Stewardship Program in 
order to monitor the appropriate use of antibiotics. In this article, the authors suggest the postulates for implementing 
the antibiotic stewardship in COVID-19 patients.
Sažetak
Posljednjih nekoliko mjeseci svijet je svjedok pandemije COVID-19 izazvane novootkrivenim koronavirusom. Zbog 
brzog i lakog širenja bolesti, kao i njezine ozbiljnosti, trenutno ova pandemija dominira svim aspektima globalnih 
zdravstvenih sustava, ali također iznimno utječe na sve aspekte našeg života, uključujući globalno gospodarstvo. 
Gotovo sve smjernice liječenja COVID-19 zagovaraju racionalnu uporabu antibiotika, ali ako analiziramo do sada 
objavljena izvješća, očito je da se oko 70% pa čak i do 100% bolesnika liječi antibioticima. Ova zlouporaba an-
tibiotika naglašava hitnu potrebu za pokretanjem programa upravljanja antimikrobnim lijekovima radi praćenja 
odgovarajuće uporabe antibiotika. U ovom članku autori predlažu postulate za primjenu programa upravljanja 
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 Last several months the World is witnessing Coro-
navirus disease 2019 (COVID-19) pandemic caused 
by the newly identified coronavirus, severe acute res-
piratory syndrome Coronavirus 2 (SARS-CoV-2). 
The outbreak started in China at the end of 2019 but 
it spread worldwide within just few months. Until 
the middle of September 2020, more than 29 million 
people were infected and more than 900.000 people 
died[1]. COVID-19 clinical presentation varies from 
asymptomatic infections to a severe life-threatening 
disease. The majority of symptomatic patients pres-
ent with fever and cough, but those requiring hospital 
admission, mostly due to dyspnea, usually have bilat-
eral radiological chest infiltrates. Severe COVID-19 
cases can present with acute respiratory distress syn-
drome (ARDS), multiple organ dysfunction syndrome 
(MODS) and even death. The studies published so far 
reported that the case fatality rate of COVID-19 varies 
from 1.4% up to 4.3%[2].
 Due to the fast and easy spread of the disease as 
well as its severity, this pandemic is currently domi-
nating every aspect of the global healthcare systems 
but also it outstandingly influences every side of our 
lives including the global economy. These are some 
of the reasons why physicians and scientists are so in-
tensively struggling to find the efficient treatment to 
alleviate this disease, but so far none of the used med-
ications are undoubtedly effective. The recommended 
treatment includes different antiviral drugs, corticos-
teroids, immunomodulatory drugs, low molecular 
weight heparin, as well as antibiotics.
 The rationale for antibiotic treatment of COV-
ID-19, which obviously is a viral disease, seems to be 
based on three different postulates. The first postulate 
is based on the previous experience with influenza 
caused by different influenza viruses, but also the ex-
perience with other Coronavirus respiratory diseases 
such as SARS and MERS. According to the previous 
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(CSS) commonly seen in COVID-19, although procal-
citonin is considered to be a rather specific acute phase 
reactant during bacterial infections[11].
 Almost all COVID-19 treatment guidelines advo-
cate the rational use of antibiotics. If we analyse the 
published reports, it is evident that at least 70% of pa-
tients received antibiotics. This proportion goes even 
up to 100% of treated patients and highlights the ur-
gent need for the introduction of the Antimicrobial 
Stewardship Program (ASP) in order to monitor the 
rational use of antibiotics and the adequate COVID-19 
patients` treatment.
 Suggested guidelines for the rational use of antibi-
otics in COVID-19
 1 Antibiotics should not be routinely adminis-
tered in patients with mild to moderate COV-
ID-19 pneumonia.
 2 Due to rather rare coinfections or superim-
posed bacterial complications in COVID-19 
pneumonia, routine antibiotics should not be 
administered in patients admitted with severe 
COVID-19 pneumonia/ARDS. In case when 
the patient, who is already admitted for more 
than 48 hours, deteriorates and develops severe 
pneumonia/ARDS, empirical treatment for no-
socomial infection has to be started as soon as 
complete sepsis workup is done. The choice of 
drug should be compliant to the antibiotic treat-
ment guidelines and local bacterial resistance 
pattern. Daily clinical and laboratory assessment 
will help in deciding about the total duration of 
antibiotic treatment.
 3 In cases where empirical antimicrobial therapy 
is prescribed in the setting of severe COVID-19 
pneumonia, frequent clinical re-evaluations are 
mandatory in order to be able to discontinue the 
empirical antibiotic treatment, if the bacterial 
superinfection is ruled out. Generally, a total du-
ration of empirical antimicrobial therapy should 
not exceed more than 5 days.
 4 The samples for microbiological tests (blood cul-
tures, sputum cultures, endotracheal secretion 
cultures, urine for legionella antigen detection) 
should be obtained prior to the introduction of 
antimicrobial therapy.
 5 If the patient is admitted with severe COVID-19 
pneumonia and empirical antibiotics are pre-
scribed, ceftriaxone is the drug of choice due to 
Streptococcus pneumoniae coverage, and once 
daily administration which spares the personal 
protective equipment consumption. Macrolides 
and fluoroquinolones should be avoided due 
to the risk of QT interval prolongation. They 
reports, in these viral pneumonias the bacterial in-
fection was present as co-infection or superinfection 
in 11 – 35% of cases so the conclusion was that the 
similar proportion of bacterial infections is to be ex-
pected in COVID-19 too[3,4]. Although the knowledge 
gap about the bacterial infection during COVID-19 
does exist, there are some published studies showing 
that the overall proportion of these infections during 
SARS-CoV-2 infection is low, especially in the disease 
early phase[5]. The majority of confirmed COVID-19 
cases do not have bacterial coinfection at the patient's 
presentation to the hospital. As per the current limited 
knowledge, at the admission, bacterial coinfection is 
seen in approximately 3.5% COVID-19 patients, and 
usually it is caused by Staphylococcus aureus, Strepto-
coccus pneumoniae or Haemophilus influenzae. At the 
same time, coinfections with atypical bacteria (e.g. 
Mycoplasma spp, Legionella spp) are rarely reported[6].
 The other reason for antibiotic use in viral disease 
is a possible antiviral activity that some antibiotics 
showed in vitro. Azithromycin, a macrolide antibiot-
ic has in vitro antiviral properties, such as decreased 
viral replication, due to blocking the viral entrance 
into the host cells. Another in vitro study demonstrat-
ed synergistic activity of the combination of hydroxy-
chloroquine and azithromycin against SARS-CoV-2[7]. 
Several other clinical studies didn’t confirm the benefit 
of azithromycin COVID-19 treatment, and because of 
the other possible side effects, like QT interval prolon-
gation, this drug is not recommended to be empiri-
cally used[8]. Some authors even suggested the use of 
teicoplanin as the new potential anti-SARS-CoV-2 
drug because it previously showed some antiviral ac-
tivity against various viruses such as Ebola virus, influ-
enza virus, flaviviruses, hepatitis C virus, HIV, and on 
Coronavirus such as MERS-CoV and SARS-CoV[9]. To 
the authors’ best knowledge there are no published re-
ports about the use of teicoplanin in COVID-19 treat-
ment so far.
 The usual differential diagnostic procedure is the 
third reason for the antibiotic treatment of COVID-19 
patients. The majority of COVID-19 patients admitted 
to the hospital are significantly sick and sometimes it 
is extremely difficult to distinguish if the disease is of 
viral or bacterial origin. In everyday work, the usu-
al inflammatory markers are used to distinguish be-
tween the two ethiologies, yet, these parameters are 
not so helpful in COVID-19. Several studies showed 
that in COVID-19, without any bacterial infection, se-
rum C-reactive protein levels can be very high, most 
probably as the result of intense immune response[10]. 
Similar to this, even serum procalcitonin levels might 
be high during the possible cytokine storm syndrome 
85
COVID-19 treatment: High time for Antimicrobial Stewardship Program    Nenad Pandak et al.    INFEKTOL GLASN 2020;40(3):83-85
REFERENCES
 [1] World Health Organisation: Coronavirus disease (COVID-19) 
pandemic. Available at: https://www.who.int/emergencies/dis-
eases/novel-coronavirus-2019. [accessed 15.9.2020.]
 [2] Du Y, Tu L, Zhu P, et al. Clinical Features of 85 Fatal Cases 
of COVID-19 from Wuhan. A Retrospective Observational 
Study. Am J Respir Crit Care Med. 2020;201(11):1372-1379.
 [3] Klein EY, Monteforte B, Gupta A, et al. The frequency of in-
fluenza and bacterial coinfection: a systematic review and me-
ta-analysis. Influenza Other Respir Viruses. 2016;10(5):394-
403.
 [4] Youngs J, Wyncoll D, Hopkins P, Arnold A, Ball J, Bicanic T. 
Improving antibiotic stewardship in COVID-19: Bacterial 
co-infection is less common than with influenza. J Infect. 2020; 
81(3): e55–e57.
 [5] Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection 
and secondary infection in patients with COVID-19: a living 
rapid review and meta-analysis. Clin Microbiol Infect. 2020; 
26(12): 1622–1629.
 [6] Sieswerda E, de Boer MGJ, Bonten MMJ, et al. Recommenda-
tions for antibacterial therapy in adults with COVID-19 – an 
evidence based guideline. Clin Microbiol Infect 2021; 27(1): 
61-66.
 [7] Gautret P, Lagier JC, Parola P, et al. Clinical and microbio-
logical effect of a combination of hydroxychloroquine and 
azithromycin in 80 COVID-19 patients with at least a six-day 
follow up: A pilot observational study. Travel Med Infect Dis. 
2020;34:101663.
 [8] Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hy-
droxychloroquine, azithromycin, and combination in patients 
hospitalized with COVID-19. Int J Infect Dis. 2020;97:396-
403.
 [9] Baron SA, Devaux C, Colson P, Raoult D, Rolain JM. Teicopla-
nin: an alternative drug for the treatment of COVID-19?. Int J 
Antimicrob Agents. 2020;55(4):105944.
 [10] Han H, Ma Q, Li C, et al. Profiling serum cytokines in COV-
ID-19 patients reveals IL-6 and IL-10 are disease severity pre-
dictors. Emerg Microbes Infect. 2020;9(1):1123-1130.
 [11] Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and 
coagulation: bleeding and thrombotic manifestations of SARS-
CoV-2 infection. Blood. 2020;136(4):489-500.
should be prescribed only if urine legionella an-
tigen is positive. If coverage for atypical bacteria 
is needed, doxycycline is considered the drug of 
choice.
 6 For patients who are mechanically ventilated 
and under ICU care, all measures should be 
dedicated to prevent ventilator associated pneu-
monia (VAP) and/or hospital acquired infection 
or pneumonia (HAI, HAP). In suspected cases 
of VAP, HAP or HAI, complete sepsis work-up 
should be done after which the empirical antibi-
otic treatment for nosocomial infections should 
be started immediately. Daily antibiotic treat-
ment assessment is mandatory taking in consid-
eration that possible CSS presentation mimics 
sepsis and/or septic shock. The duration of anti-
biotic treatment depends on clinical assessment, 
laboratory and microbiology test results.
 7 Antimicrobial stewardship teams (AST) con-
ducting the antimicrobial stewardship program 
(ASP) remains the integral part of the treatment 
decisions related to COVID-19 pandemic. The 
ASP activities are important for all COVID-19 
patients, but especially for those hospitalized in 
the ICU setting. The AST work in developing 
the treatment protocols is essential for adequate 
treatment of COVID-19 patients and at the same 
time controlling the antibiotic consumption that 
influences the bacterial resistance spreading.
The only COVID-19 comprehensive solution shall be 
the efficient vaccine. Until it is available, we have to 
continue the treatment with medications that we have 
at present. This means that occasionally we are going 
to witness the antibiotic overuse and misuse, but we 
have to continue the hard work on implementing the 
ASP and appropriate antibiotic use in COVID-19 pa-
tients. Even when we succeed to prevent the SARS-
CoV-2 infection with future vaccines, this pandemic 
should be considered as the turning point in human 
history as it clearly shows that only united humanity 
can overcome the global threat like this disease.
